Ticker Details
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S and NeuVax.
IPO Date:	April 1, 2008
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$906.89M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 3.51%
Avg Daily Range (30 D):	$0.27 | 5.43%
Avg Daily Range (90 D):	$0.20 | 5.35%

Institutional Daily Volume
Avg Daily Volume:	1.02M
Avg Daily Volume (30 D):	6.68M
Avg Daily Volume (90 D):	7.62M

Trade Size
Avg Trade Size (Sh.):	462
Avg Trade Size (Sh.) (30 D):	246
Avg Trade Size (Sh.) (90 D):	310

Institutional Trades
Total Institutional Trades:	177
Avg Institutional Trade:	$1.8M
Avg Institutional Trade (30 D):	$2.59M
Avg Institutional Trade (90 D):	$1.99M
Avg Institutional Trade Volume:	.47M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.07M
Avg Closing Trade (30 D):	$3.44M
Avg Closing Trade (90 D):	$2.22M
Avg Closing Volume:	547.74K

News

Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire

Jul 16, 2025 @ 10:51 PM Cancer Pipeline Milestones Coming Fast as Regulato... Source: Prnewswire

Jun 2, 2025 @ 12:00 PM SELLAS Presents Preclinical Efficacy of SLS009 in ... Source: Sellas Life Sciences Group, Inc.

May 12, 2025 @ 5:00 PM Blood Cancer Treatment Market Sees Accelerated Gro... Source: Delveinsight

Feb 27, 2025 @ 3:04 PM Oncology Breakthroughs: How Cancer Research Is Adv... Source: Prnewswire

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.25	$-.05	$-.25
Diluted EPS	$-.25	$-.05	$-.25
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-26.86M	$-7.66M	$-26.86M
Operating Income / Loss	$-28.27M	$-8.26M	$-28.27M
Cost of Revenue	$M	$M	$M
Net Cash Flow	$M	$M	$M
PE Ratio

Splits
Nov 08, 2019	1:50
Jan 02, 2018	1:30
Nov 14, 2016	1:20